Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DeltaRex-G in symptomatic COVID-19
NCT04378244Phase 2Withdrawn
- Sponsor
- Aveni Foundation
- Start
- Dec 2022
- Primary completion
- Dec 2023
- Modality
- Gene Editing, Nanoparticles, Gene Silencing
01
Overview
Phase 2, randomised, open-label trial of deltarex-g in coronavirus disease 2019 (COVID-19), sponsored by Aveni Foundation. Primary endpoints: Dose Limiting Toxicity at 3 weeks, Maximum Tolerated Dose at 3 weeks and 1 more. Planned start Dec 2022; status: withdrawn.
02
Drugs
deltarex-g
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04378244.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04378244.